Buenos Aires - Delayed Quote ARS

Novartis AG (NVS.BA)

26,001.00

+101.00

(+0.39%)

As of 11:07 AM GMT-3. Market Open.

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Investor's Business Daily 2 hours ago

NVS
Novartis bags paediatric FDA label expansion for Lutathera

Lutathera is approved by the US FDA to treat patients aged 12 years and older with rare gastroenteropancreatic neuroendocrine cancer.

Pharmaceutical Technology 23 hours ago

NVS
Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript

Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript April 23, 2024 Novartis AG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and good afternoon, and welcome to the Novartis Q1 2024 Results Release Conference Call and Live Webcast. […]

Insider Monkey yesterday

NVS
Company News for Apr 24, 2024

Companies in The News Are: UPS,PM,NVS,IVZ

Zacks yesterday

UPS

PM

NVS
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem

GlobeNewswire yesterday

NVS

NVSEF
Why Novartis Stock Topped the Market on Tuesday

A double beat on the latest quarterly results and raised guidance made investors happy.

Motley Fool yesterday

NVS

^GSPC
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Related: Novartis Stock Gains On European Drugm

Benzinga yesterday

NVS
How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint

Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.

Investor's Business Daily yesterday

NVS
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra

GlobeNewswire yesterday

NVS

NVSEF
Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock

Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock

PREMIUM
MT Newswires yesterday

AAPL

PM

UPS
Novartis Stock Jumps After Beating Expectations, Raising Guidance

Shares of Swiss drugmaker Novartis rallied after the company’s first-quarter sales surpassed analysts’ expectations, and it raised its full-year guidance. Novartis executives touted strong sales across major brands on an analyst call on Tuesday. The pharmaceutical company reported $11.8 billion in first-quarter net sales—higher than analysts' estimates, and fueled by more than $1 billion in quarterly sales for both heart-failure drug Entresto and psoriasis drug Cosentyx.

The Wall Street Journal yesterday

NVS

NVSEF
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript

NVS earnings call for the period ending March 31, 2024.

Motley Fool yesterday

NVS
Novartis raises full-year guidance on Q1 beat, drug sales

Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith

Yahoo Finance Video 2 days ago

NVS

NVSEF
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

Zacks 2 days ago

INCY

NVS
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics

The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 2 days ago

NVS
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.

Zacks 2 days ago

NVS
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger

Novartis, American Express, ConocoPhillips, Netflix and Schlumberger are part of the Zacks top Analyst Blog.

Zacks 2 days ago

COP

AXP

NVS
Former Bristol Myers CEO tapped as Novartis’ next board chair

Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.

BioPharma Dive 2 days ago

NVS

CELG-RT
Novartis raises forecasts as top drug sales beat Wall Street estimates

Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.

BioPharma Dive 2 days ago

NVS
Trending tickers: Tesla, ABF, Novartis, Taylor Wimpey, JD Sports

The latest investor updates on stocks that are trending on Tuesday.

Yahoo Finance UK 2 days ago

TSLA

NKE

GBPUSD=X

Performance Overview

Return	NVS.BA	MSCI WORLD
YTD	+7.58%	+3.69%
1-Year	+128.70%	+16.25%
3-Year	+688.16%	+11.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NVS.BA)

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

Novartis bags paediatric FDA label expansion for Lutathera

Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript

Company News for Apr 24, 2024

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Why Novartis Stock Topped the Market on Tuesday

FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock

Novartis Stock Jumps After Beating Expectations, Raising Guidance

Novartis Ag (NVS) Q1 2024 Earnings Call Transcript

Novartis raises full-year guidance on Q1 beat, drug sales

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics

Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger

Former Bristol Myers CEO tapped as Novartis’ next board chair

Novartis raises forecasts as top drug sales beat Wall Street estimates

Trending tickers: Tesla, ABF, Novartis, Taylor Wimpey, JD Sports

Performance Overview